Amarin Seeks ITC Action Against Products 'Cloaked' As Dietary Supplements
Executive Summary
Seeking to protect its competitive interests, Vascepa marketer asks the US International Trade Commission to investigate importation and sale of synthetically produced omega-3 products by 18 companies; complaint asserts the products at issue are unapproved new drugs that are illegally being marketed as dietary supplements.
You may also be interested in...
AbbVie’s Battle Over Alvotech’s Humira Biosimilar Moves To New Ground With ITC Investigation
International Trade Commission launches investigation of adalimumab manufacturing processes in response to AbbVie complaint of misappropriation of trade secrets. District court dismissed trade secret suit on grounds it lacked jurisdiction. Trial in infringement suit is set for August.
AbbVie’s Battle Over Alvotech’s Biosimilar Humira Moves To New Ground With ITC Investigation
International Trade Commission launches investigation of adalimumab manufacturing processes in response to AbbVie complaint of misappropriation of trade secrets. District court dismissed trade secret suit on grounds it lacked jurisdiction. Trial in infringement suit is set for August.
FDA Objects To Amarin Trade Complaint Against Omega-3 Ingredients
FDA Chief Counsel Rebecca Wood says Amarin's request for an ITC investigation necessarily turns on questions of drug and supplements policy, where it is the expert and authorized agency. If successful, Amarin's move could encourage others to similarly seek alternative forums for action.